Adverum Biotechnologies (ADVM) Stock Price, News & Analysis

Company Overview

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $2.27 to $2.43
• 50-Day Range: $2.15 to $2.97
• 52-Week Range: $1.78 to $8.56
• Volume: 79,688 shs
• Average Volume: 117,764 shs
• Market Capitalization: $48.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.80
• Consensus Rating: Moderate Buy

Adverum Biotechnologies Stock Analysis - MarketRank™

Adverum Biotechnologies scored higher than 85% of companies evaluated by MarketBeat, and ranked 131st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adverum Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Adverum Biotechnologies has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($4.92) to ($5.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adverum Biotechnologies is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adverum Biotechnologies is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adverum Biotechnologies has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.45% of the float of Adverum Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

Adverum Biotechnologies has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adverum Biotechnologies has recently decreased by 11.21%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adverum Biotechnologies does not currently pay a dividend.

Dividend Growth

Adverum Biotechnologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.78

Percentage of Shares Shorted

7.45% of the float of Adverum Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

Adverum Biotechnologies has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adverum Biotechnologies has recently decreased by 11.21%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Adverum Biotechnologies has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Adverum Biotechnologies this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Adverum Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,020.00 in company stock.

Percentage Held by Insiders

Only 6.00% of the stock of Adverum Biotechnologies is held by insiders.

Percentage Held by Institutions

48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADVM Stock Analysis - Frequently Asked Questions

How have ADVM shares performed this year?

Adverum Biotechnologies' stock was trading at $4.67 at the beginning of the year. Since then, ADVM stock has decreased by 50.3% and is now trading at $2.32.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) issued its quarterly earnings results on Tuesday, April, 15th. The biotechnology company reported ($1.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.34) by $0.62.

When did Adverum Biotechnologies' stock split?

Adverum Biotechnologies's stock reverse split on the morning of Thursday, March 21st 2024.The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Adverum Biotechnologies' major shareholders?

Top institutional shareholders of Adverum Biotechnologies include Y Intercept Hong Kong Ltd (0.10%). Insiders that own company stock include Braden Michael Leonard, Laurent Fischer, Peter Soparkar, Setareh Seyedkazemi, Brigit Riley, James Paul Scopa and Richard Beckman.
View institutional ownership trends.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adverum Biotechnologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 4/15/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADVM
• CIK: 1501756
• Web: www.adverum.com
• Phone: (650) 656-9323
• Fax: 650-329-8151
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Adverum Biotechnologies: $23.80
• High Price Target: $40.00
• Low Price Target: $4.00
• Potential Upside/Downside: +925.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.93 million
• Net Margins: N/A
• Pretax Margin: -15,079.90%
• Return on Equity: -130.53%
• Return on Assets: -66.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.57
• Quick Ratio: 3.57

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 48.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.40 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 20,890,000
• Free Float: 19,638,000
• Market Cap: $48.46 million
• Optionable: Optionable
• Beta: 0.77